Elaine Shum, MD
Hematology & Oncology · New York, NYNPI 1164716296
Payments from drug & device makers
Across 647 payments — averaging $7096.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$2.6M
- Genentech, Inc.$783K
- Daiichi Sankyo Inc.$558K
- Spectrum Pharmaceuticals Inc.$155K
- AstraZeneca$125K
- Genmab U.S., Inc.$121K
- plus $288K from 18 others
Across 4 payments — averaging $1028.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 163 | $2,562,013 |
| Genentech, Inc. | 168 | $783,176 |
| Daiichi Sankyo Inc. | 52 | $557,659 |
| Spectrum Pharmaceuticals Inc. | 21 | $154,746 |
| AstraZeneca | 71 | $125,237 |
| Genmab U.S., Inc. | 13 | $120,713 |
| Boehringer Ingelheim | 15 | $71,466 |
| Incyte Corporation | 15 | $50,792 |
| AbbVie | 2 | $44,313 |
| E.r. Squibb & Sons, L.L.C. | 14 | $42,173 |
| Astrazeneca UK Limited | 34 | $31,770 |
| Johnson & Johnson | 10 | $9,783 |
| Medical Device Business Services, Inc. | 9 | $8,910 |
| Regeneron | 12 | $8,520 |
| Eli Lilly | 2 | $6,000 |
| Janssen Global Services, LLC | 4 | $3,617 |
| Boehringer Ingelheim International GmbH | 14 | $3,581 |
| Gilead | 1 | $2,570 |
| Regeneron Healthcare Solutions, Inc. | 3 | $1,424 |
| Genentech USA, Inc. | 10 | $1,337 |
| Janssen Scientific Affairs, LLC | 1 | $1,010 |
| Jazz Pharmaceuticals Inc. | 4 | $474 |
| Tempus AI, Inc | 8 | $191 |
| Mirati Therapeutics, Inc. | 1 | $29 |
How this compares
$4,591,502 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New York
- Vicky MakkerNew York$27.1M
- Alison MoskowitzNew York$22.7M
- Ajai ChariNew York$22.4M
- Yelena JanjigianNew York$16.9M
- Alexander LesokhinNew York$11.9M
- John MascarenhasNew York$11.8M
- Maria PalombaNew York$11.6M
- Scott TagawaNew York$10.3M
- Mohammad Abdul HayNew York$9.9M
- Joshua SabariNew York$9.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.